|
||||||||||||||||||||||
|
|
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Basic Trial Information
Summary This single arm study will evaluate the efficacy, safety and impact on quality of life of treatment with oral Xeloda plus intravenous Taxotere (docetaxel) in patients with HER2-neu negative breast cancer, and in combination with iv Herceptin (trastuzumab) in patients with HER2-neu positive breast cancer. Patients will receive 3-weekly cycles of treatment with Xeloda (825mg/m2 po bid on days 1-14) + Taxotere (75mg/m2 iv on day 1). HER2-neu positive patients will also receive Herceptin (loading dose of 4mg/kg iv followed by 2mg/kg iv weekly). The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals. Eligibility Criteria Inclusion Criteria:
Exclusion Criteria:
Trial Lead Organizations/Sponsors F. Hoffmann - La Roche, Limited
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |